KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EBITDA (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed EBITDA for 6 consecutive years, with -$108.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 41.05% year-over-year to -$108.3 million, compared with a TTM value of -$648.1 million through Dec 2025, down 38.34%, and an annual FY2025 reading of -$648.1 million, down 35.31% over the prior year.
  • EBITDA was -$108.3 million for Q4 2025 at Recursion Pharmaceuticals, up from -$172.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$30.5 million in Q1 2021 and bottomed at -$191.4 million in Q1 2025.
  • Average EBITDA over 5 years is -$94.0 million, with a median of -$84.0 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 153.94% in 2021, then surged 41.05% in 2025.
  • Year by year, EBITDA stood at -$65.0 million in 2021, then increased by 6.12% to -$61.0 million in 2022, then crashed by 62.23% to -$98.9 million in 2023, then crashed by 85.75% to -$183.8 million in 2024, then soared by 41.05% to -$108.3 million in 2025.
  • Business Quant data shows EBITDA for RXRX at -$108.3 million in Q4 2025, -$172.2 million in Q3 2025, and -$176.2 million in Q2 2025.